AIM
KYNB

Acrospire Investment Management’s Kyntra Bio KYNB Stock Holding History

Acrospire Investment Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-29
Closed -$24K – 515
2017
Q2 		$24K Sell
29
-120
-81% -$83.6K 0.02% 1415
2017
Q1 		$92K Sell
149
-228
-60% -$139K 0.08% 371
2016
Q4 		$202K Buy
377
+335
+798% +$167K 0.08% 352
2016
Q3 		$22K Sell
42
-224
-84% -$106K 0.01% 1465
2016
Q2 		$109K Buy
266
+188
+241% +$86.1K 0.08% 375
2016
Q1 		$42K Buy
+78
New +$38.9K 0.03% 1096

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Acrospire Investment Management's KYNB Position: Q3 2017 in Review

Acrospire Investment Management sold out of Kyntra Bio (KYNB) in Q3 2017, closing a stake of 29 shares — an estimated $24K sold.

Acrospire Investment Management first reported a position in KYNB in Q1 2016 and held it in 6 quarters. The position peaked at $202K in Q4 2016. 182 funds tracked by Wall St. Rank hold KYNB as of Q3 2017.

  • Acrospire Investment Management reported no remaining Kyntra Bio position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 29 Kyntra Bio shares in Q3 2017, an estimated $24K.
  • Acrospire Investment Management first reported a position in Kyntra Bio in Q1 2016 and held it in 6 quarters.
  • Acrospire Investment Management's Kyntra Bio position peaked at $202K in Q4 2016.
  • 182 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.